IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study
Journal
Liver cancer
Journal Volume
12
Journal Issue
3
Date Issued
2023-08
Author(s)
Kudo, Masatoshi
Finn, Richard S
Galle, Peter R
Zhu, Andrew X
Ducreux, Michel
Ikeda, Masafumi
Tsuchiya, Kaoru
Aoki, Ken-Ichi
Jia, Jing
Lencioni, Riccardo
Abstract
The phase III IMbrave150 study established atezolizumab + bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) stage B disease.
Subjects
Atezolizumab; Barcelona Clinic Liver Cancer stage B; Bevacizumab; Unresectable hepatocellular carcinoma
SDGs
Type
journal article